CALTCalliditas Therapeutics AB

Nasdaq calliditas.se


$ 38.00 $ 15.53 (69.27 %)    

Tuesday, 28-May-2024 15:36:19 EDT
QQQ $ 454.82 $ 1.73 (0.38 %)
DIA $ 398.57 $ -2.04 (-0.52 %)
SPY $ 530.36 $ 0.37 (0.07 %)
TLT $ 91.26 $ -1.31 (-1.43 %)
GLD $ 225.37 $ 2.27 (1.05 %)
$ 37.95
$ 38.22
$ 0.00 x 0
$ 0.00 x 0
$ 37.83 - $ 38.22
$ 15.25 - $ 38.32
217,688
na
2.26B
$ 0.93
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 jefferies-downgrades-calliditas-therapeutics-to-hold-lowers-price-target-to-39

Jefferies analyst Maury Raycroft downgrades Calliditas Therapeutics (NASDAQ:CALT) from Buy to Hold and lowers the price targ...

 stifel-downgrades-calliditas-therapeutics-to-hold-lowers-price-target-to-40

Stifel analyst Annabel Samimy downgrades Calliditas Therapeutics (NASDAQ:CALT) from Buy to Hold and lowers the price target ...

 asahi-kasei-makes-11b-offer-for-swedish-drugmaker-calliditas-therapeutics-enhancing-pharma-growth-strategy

Asahi Kasei's $1.1 billion acquisition of Calliditas Therapeutics offers 208 SEK per share in cash. The deal boosts Asahi K...

 hc-wainwright--co-downgrades-calliditas-therapeutics-to-neutral-announces-39-price-target

HC Wainwright & Co. analyst Arthur He downgrades Calliditas Therapeutics (NASDAQ:CALT) from Buy to Neutral and announces...

 calliditas-therapeutics-board-unanimously-recommends-acceptance-of-asahi-kaseis-sek-1116b-tender-offer

STOCKHOLM, May 28, 2024 /PRNewswire/ -- The Board of Directors of Calliditas Therapeutics AB (publ) unanimously recommends that...

 hc-wainwright--co-maintains-buy-on-calliditas-therapeutics-lowers-price-target-to-45

HC Wainwright & Co. analyst Arthur He maintains Calliditas Therapeutics (NASDAQ:CALT) with a Buy and lowers the price ta...

 calliditas-therapeutics-q1-eps-088-down-from-033-yoy-sales-2843m-up-from-1832m-yoy

Calliditas Therapeutics (NASDAQ:CALT) reported quarterly losses of $(0.88) per share. This is a 163.47 percent decrease over lo...

 calliditas-therapeutics-reports-data-from-phase-2-study-of-setanaxib-in-combination-with-pembrolizumab-for-head-and-neck-cancer

 Calliditas Therapeutics AB (NASDAQ:CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced data from the proof-...

 calliditas-announces-nefigard-open-label-extension-results

Calliditas Therapeutics AB (NASDAQ:CALT), (NASDAQ STOCKHOLM: CALTX) ("Calliditas") today announced that the global open...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION